logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics taps Knox Communications to carry out marketing and investor relations

KCI's founder and principal, Knox Henderson, brings more than 25 years' experience in investor relations, corporate finance and communications for publicly listed companies

XPhyto Therapeutics Corp. - XPhyto Therapeutics Corp taps Knox Communications Inc to carry out marketing and investor communication activities for the company
XPhyto said the agreement became effective July 1 for 12 months and that it has granted Henderson stock options to purchase 100,000 common shares at $2.50 apiece for a period of one year

XPhyto Therapeutics Corp (CSE:XPHY) (FSE:4XT) (OTCPINK:XPHYF) said Wednesday it has entered into an investor-relations consulting agreement with Knox Communications Inc (KCI) to carry out marketing and investor communication activities for the company.

KCI's founder and principal, Knox Henderson, brings more than 25 years' experience in investor relations, corporate finance and communications for publicly listed companies, XPhoto noted in a statement.

READ: XPhyto Therapeutics partners with German biotech firm to develop coronavirus screening test

Henderson has advised a broad range of early and growth-stage companies in the life sciences, technology and resource sectors, it added. His most recent major engagement involves notable success in the Canadian junior capital markets.

The company noted that Henderson was formerly a CSC-designated trader on the Canadian equities markets.

XPhyto said the agreement became effective July 1 for a term of 12 months and that it has granted Henderson stock options to purchase 100,000 common shares at $2.50 apiece for a period of one year. The options will vest in four equal tranches over the term of the agreement beginning three months from issuance.

Vancouver-based XPhyto is a biopharma, diagnostics and cannabis science company focused on formulation, clinical validation, and European imports, distribution and sales.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: XPhyto Therapeutics Corp.

Price: 3.1 CAD

CSE:XPHY
Market: CSE
Market Cap: $168.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

XPhyto Therapeutics partner 3A revives grant from German Ministry of...

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive Vancouver to bring news their German partner 3aDiagnostics and their contract research collaborators, have received a grant from the German Federal Ministry of Education and Research. Roger telling Proactive...

on 06/12/2020

2 min read